Dafna Capital Management
$524M 13F equity value
96 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Dafna Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 562,630 | $105M | 20.1% |
| XBI | SPDR S&P BIOTECH ETF | 196,505 | $31M | 5.9% |
| CMPS | COMPASS PATHWAYS PLC | 2,011,952 | $28M | 5.4% |
| STXS | STEREOTAXIS INC | 13,680,554 | $24M | 4.5% |
| NKTR | NEKTAR THERAPEUTICS | 318,380 | $22M | 4.2% |
| DNLI | DENALI THERAPEUTICS INC | 739,014 | $19M | 3.6% |
| IDYA | IDEAYA BIOSCIENCES INC | 497,240 | $19M | 3.5% |
| ATRC | ATRICURE INC | 597,431 | $17M | 3.2% |
| XENE | XENON PHARMACEUTICALS INC | 250,772 | $15M | 2.9% |
| CYTK | CYTOKINETICS INC | 171,998 | $15M | 2.8% |
Track Dafna Capital Management's 13F portfolio: $524M in reported holdings, 96 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}